advertisement
Chung Y 13
Showing records 1 to 13 | Display all abstracts from Chung Y112854 COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan&re
Kandarakis S
Expert Opinion on Drug Safety 2023; 0: 1-12
112340 A new model of axon degeneration in the mouse optic nerve using repeat intraocular pressure challenge
Chrysostomou V; Bell KC
Experimental Eye Research 2024; 238: 109722
112854 COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan&re
Papadopoulos AP; Roussopoulos G
Expert Opinion on Drug Safety 2023; 0: 1-12
112340 A new model of axon degeneration in the mouse optic nerve using repeat intraocular pressure challenge
Ng SW
Experimental Eye Research 2024; 238: 109722
112854 COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan&re
Georgopoulos E
Expert Opinion on Drug Safety 2023; 0: 1-12
112340 A new model of axon degeneration in the mouse optic nerve using repeat intraocular pressure challenge
Suresh S
Experimental Eye Research 2024; 238: 109722
112854 COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan&re
Chung Y
Expert Opinion on Drug Safety 2023; 0: 1-12
112340 A new model of axon degeneration in the mouse optic nerve using repeat intraocular pressure challenge
Karthik G; Millet M
Experimental Eye Research 2024; 238: 109722
112854 COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan&re
Doumazos L
Expert Opinion on Drug Safety 2023; 0: 1-12
112340 A new model of axon degeneration in the mouse optic nerve using repeat intraocular pressure challenge
Chung Y
Experimental Eye Research 2024; 238: 109722
112854 COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan&re
Baek A; Paizi NI
Expert Opinion on Drug Safety 2023; 0: 1-12
112340 A new model of axon degeneration in the mouse optic nerve using repeat intraocular pressure challenge
Crowston JG
Experimental Eye Research 2024; 238: 109722
112854 COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan&re
Shin H; Papadopoulos PA
Expert Opinion on Drug Safety 2023; 0: 1-12
